9/28/2021 8:17:55 AM
Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO, Oral Testosterone Product
8/25/2021 6:34:56 AM
Lipocine's LPCN 1144 Meets NASH Resolution Regulatory Endpoint In Phase 2 LiFT Study
8/5/2021 8:15:05 AM
Lipocine Q2 Net Loss Of $6.8 Mln Or $0.08/shr Vs. Loss Of $6.4 Mln Or $0.13/shr Prior Year
7/14/2021 4:08:55 PM
Lipocine Announces Settlement With Clarus Therapeutics
5/26/2021 8:47:48 AM
Lipocine Says Disappointed In Court' Decision Of Granting Clarus Therapeutics' Motion For Summary Judgment
3/11/2021 8:19:02 AM
Lipocine 2020 Net Loss $21.0 Mln Or $0.38/Shr Vs Net Loss $13.0 Mln Or $0.50/Shr Last Year
1/26/2021 9:02:22 AM
Lipocine Prices Public Offering Of 14.28 Mln Shares At $1.75/Shr
1/25/2021 4:11:46 PM
Lipocine Intends To Offer Shares Of Its Common Stock
1/14/2021 8:07:11 AM
Lipocine Reports USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications
1/12/2021 8:11:20 AM
Lipocine Announces Positive Topline Phase 2 Results From LPCN 1144 Ongoing LiFT Study; Stock Surges
12/30/2020 8:07:20 AM
Lipocine Says Enrolling Patients Into Open Label Extension To Ongoing LPCN 1144 Phase 2 LiFT Study
12/29/2020 8:07:32 AM
Lipocine Updates On Jury Trial In Patent Infringement Lawsuit Against Clarus; Trial Postponed To February 8